[1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
|
[2] |
Zhu H, Ma X, Ye T, et al. Esophageal cancer in China: practice and research in the new era[J]. Int J Cancer, 2023, 152(9): 1741-1751. DOI: 10.1002/ijc.34301.
|
[3] |
Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial[J]. Lancet, 2012, 379(9829): 1887-1892. DOI: 10.1016/S0140-6736(12)60516-9.
pmid: 22552194
|
[4] |
van der Sluis PC, van der Horst S, May AM, et al. Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: a randomized controlled trial[J]. Ann Surg, 2019, 269(4): 621-630. DOI: 10.1097/SLA.0000000000003031.
pmid: 30308612
|
[5] |
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22): 2074-2084. DOI: 10.1056/NEJMoa1112088.
|
[6] |
Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27): 2796-2803. DOI: 10.1200/JCO.2018.79.1483.
|
[7] |
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125.
|
[8] |
Zheng Y, Li Y, Liu X, et al. Right compared with left thoracic approach esophagectomy for patients with middle esophageal squamous cell carcinoma[J]. Front Oncol, 2020, 10: 536842. DOI: 10.3389/fonc.2020.536842.
|
[9] |
Duan X, Bai W, Ma Z, et al. Management and outcomes of anastomotic leakage after McKeown esophagectomy: a retrospective analysis of 749 consecutive patients with esophageal cancer[J]. Surg Oncol, 2020, 34: 304-309. DOI: 10.1016/j.suronc.2020.06.002.
pmid: 32891347
|
[10] |
Zhang H, Chen L, Geng Y, et al. Modified anastomotic technique for thoracolaparoscopic Ivor Lewis esophagectomy: early outcomes and technical details[J]. Dis Esophagus, 2017, 30(1): 1-5. DOI: 10.1093/dote/dow021.
pmid: 27061221
|
[11] |
Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer[J]. N Engl J Med, 2019, 380(2): 152-162. DOI: 10.1056/NEJMoa1805101.
|
[12] |
Yibulayin W, Abulizi S, Lv H, et al. Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis[J]. World J Surg Oncol, 2016, 14(1): 304. DOI: 10.1186/s12957-016-1062-7.
|
[13] |
Levy RM, Wizorek J, Shende M, et al. Laparoscopic and thoracoscopic esophagectomy[J]. Adv Surg, 2010, 44: 101-116. DOI: 10.1016/j.yasu.2010.05.002.
pmid: 20919517
|
[14] |
Pennywell D, Sarkaria IS. Robotic assisted minimally invasive esophagectomy for esophageal cancer: a comment on the Ruijin hospital experience[J]. J Thorac Dis, 2017, 9(9): 2888-2890. DOI: 10.21037/jtd.2017.08.153.
pmid: 29220041
|
[15] |
Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
|
[16] |
Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 rando-mized clinical trial[J]. JAMA Surg, 2021, 156(8): 721-729. DOI: 10.1001/jamasurg.2021.2373.
|
[17] |
He W, Leng X, Mao T, et al. Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma[J]. Oncologist, 2022, 27(1): e18-e28. DOI: 10.1093/oncolo/oyab011.
|
[18] |
Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J]. Eur J Cancer, 2021, 144: 232-241. DOI: 10. 1016/j.ejca.2020.11.039.
pmid: 33373868
|
[19] |
Chen Y, Ren M, Li B, et al. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase Ⅱ clinical trial (CY-NICE)[J]. J Thorac Dis, 2023, 15(12): 6761-6775. DOI: 10.21037/jtd-23-1388.
|
[20] |
Yang W, Xing X, Yeung SCJ, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(1): e003497. DOI: 10.1136/jitc-2021-003497.
|
[21] |
Chen B, Liu S, Zhu Y, et al. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab[J]. Nat Commun, 2024, 15(1): 1919. DOI: 10.1038/s41467-024-46307-7.
|
[22] |
Wu H, Shang L, Du F, et al. Transhiatal versus transthoracic surgical approach for siewert type Ⅱ adenocarcinoma of the esophagogastric junction: a meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(11): 1107-1117. DOI: 10.1080/17474124. 2020.1806710.
|
[23] |
Mortensen K, Nilsson M, Slim K, et al. Consensus guidelines for enhanced recovery after gastrectomy: enhanced recovery after surgery (ERAS®) society recommendations[J]. Br J Surg, 2014, 101(10): 1209-1229. DOI: 10.1002/bjs.9582.
pmid: 25047143
|
[24] |
Low DE, Allum W, De Manzoni G, et al. Guidelines for perioperative care in esophagectomy: enhanced recovery after surgery (ERAS®) society recommendations[J]. World J Surg, 2019, 43(2): 299-330. DOI: 10.1007/s00268-018-4786-4.
|
[25] |
Huang Y, Xie Q, Wei X, et al. Enhanced recovery protocol versus conventional care in patients undergoing esophagectomy for cancer: advantages in clinical and patient-reported outcomes[J]. Ann Surg Oncol, 2024, 31(9): 5706-5716. DOI: 10.1245/s10434-024-15509-0.
pmid: 38833056
|
[26] |
Chen J, Zhao Y, Yang W, et al. Pulmonary infection after esophageal cancer surgery: impact on the reality, risk factors and development of a predictive nomogram[J]. World J Surg Oncol, 2025, 23(1): 149. DOI: 10.1186/s12957-025-03806-1.
|
[27] |
Zhao L, He J, Qin Y, et al. Application of intraoperative nerve monitoring for recurrent laryngeal nerves in minimally invasive McKeown esophagectomy[J]. Dis Esophagus, 2022, 35(7): doab080. DOI: 10.1093/dote/doab080.
|
[28] |
Koyanagi K, Ozawa S, Ninomiya Y, et al. Indocyanine green fluorescence imaging for evaluating blood flow in the reconstructed conduit after esophageal cancer surgery[J]. Surg Today, 2022, 52(3): 369-376. DOI: 10.1007/s00595-021-02296-4.
|
[29] |
Fabbi M, Hagens ERC, van Berge Henegouwen MI, et al. Anastomotic leakage after esophagectomy for esophageal cancer: definitions, diagnostics, and treatment[J]. Dis Esophagus, 2021, 34(1): doaa039. DOI: 10.1093/dote/doaa039.
|
[30] |
Low DE, Alderson D, Cecconello I, et al. International consensus on standardization of data collection for complications associated with esophagectomy: Esophagectomy Complications Consensus Group (ECCG)[J]. Ann Surg, 2015, 262(2): 286-294. DOI: 10.1097/SLA.0000000000001098.
pmid: 25607756
|
[31] |
Kumagai Y, Hatano S, Sobajima J, et al. Indocyanine green fluorescence angiography of the reconstructed gastric tube during esophagectomy: efficacy of the 90-second rule[J]. Dis Esophagus, 2018, 31(12): doy052. DOI: 10.1093/dote/doy052.
|
[32] |
Takeda S, Iida M, Kanekiyo S, et al. Efficacy of intraoperative recurrent laryngeal neuromonitoring during surgery for esophageal cancer[J]. Ann Gastroenterol Surg, 2021, 5(1): 83-92. DOI: 10. 1002/ags3.12394.
pmid: 33532684
|
[33] |
Huang P, Yang J, Zhao D, et al. Machine learning-based prediction of early complications following surgery for intestinal obstruction: multicenter retrospective study[J]. J Med Internet Res, 2025, 27: e68354. DOI: 10.2196/68354.
|